TABLE 4.
Population simulation of dalbavancin at 1,500 mg administered intravenously on pharmacodynamic targets for clinically relevant bacteria
| Compartment | % of Staphylococcus isolates |
% of Streptococcus isolates |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC (mg/liter) |
EUCAST breakpoint |
MIC (mg/liter) |
EUCAST breakpointc | ||||||||||
| 0.25 | 0.5 | 1 | 1.5 | 2 | MRSAa | Staphylococcus spp.b | 0.25 | 0.5 | 1 | 1.5 | 2 | ||
| Plasma | 100 | 100 | 100 | 100 | 99.99 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Peritoneal dialysate | 96.67 | 92.74 | 83.85 | 72.07 | 60.06 | 92.96 | 95.64 | 99.59 | 99.44 | 98.65 | 98.09 | 97.11 | 99.98 |
a
The MIC distribution for MRSA strains was as follows: 0.125 mg/liter, 4%; 0.25 mg/liter, 29%; 0.5 mg/liter, 54%; 1 mg/liter, 13%.
b
The MIC distribution for Staphylococcus spp. was as follows: 0.064 mg/liter, 2%; 0.125 mg/liter, 22%; 0.25 mg/liter, 51%; 0.5 mg/liter, 23%; 1 mg/liter, 2%.
c
The MIC distribution for Streptococcus spp. according to EUCAST breakpoints was as follows: 0.002 mg/liter, 1%; 0.004 mg/liter, 1%; 0.008 mg/liter, 17%; 0.016 mg/liter, 53%; 0.032 mg/liter, 14%; 0.064 mg/liter, 10%; 0.125 mg/liter, 3%; 0.25 mg/liter, 1%.